Your browser is no longer supported. Please, upgrade your browser.
Settings
MRK Merck & Co. Inc. daily Stock Chart
MRK [NYSE]
Merck & Co. Inc.
IndexDJIA S&P500 P/E35.02 EPS (ttm)1.57 Insider Own0.04% Shs Outstand2.79B Perf Week-3.35%
Market Cap152.95B Forward P/E14.45 EPS next Y3.79 Insider Trans-5.18% Shs Float2.77B Perf Month3.65%
Income4.44B PEG7.15 EPS next Q0.85 Inst Own75.20% Short Float1.04% Perf Quarter9.18%
Sales39.50B P/S3.87 EPS this Y-61.60% Inst Trans0.10% Short Ratio2.87 Perf Half Y1.27%
Book/sh16.02 P/B3.42 EPS next Y1.99% ROA4.30% Target Price61.60 Perf Year-4.79%
Cash/sh4.81 P/C11.39 EPS next 5Y4.90% ROE9.60% 52W Range44.52 - 59.67 Perf YTD4.73%
Dividend1.84 P/FCF25.40 EPS past 5Y41.50% ROI6.40% 52W High-8.09% Beta0.68
Dividend %3.36% Quick Ratio1.30 Sales past 5Y-3.00% Gross Margin63.10% 52W Low23.17% ATR0.81
Employees68000 Current Ratio1.50 Sales Q/Q-2.50% Oper. Margin17.50% RSI (14)47.07 Volatility1.27% 1.51%
OptionableYes Debt/Eq0.59 EPS Q/Q-86.30% Profit Margin11.20% Rel Volume1.33 Prev Close55.74
ShortableYes LT Debt/Eq0.54 EarningsMay 05 BMO Payout114.60% Avg Volume9.97M Price54.84
Recom2.50 SMA20-1.66% SMA502.71% SMA2004.19% Volume13,227,664 Change-1.61%
Apr-06-16Initiated Societe Generale Buy $80
Jan-27-16Downgrade BofA/Merrill Buy → Neutral
Dec-01-15Upgrade Barclays Equal Weight → Overweight $64 → $66
Nov-24-15Initiated Berenberg Hold
Nov-17-15Reiterated Argus Buy $70 → $65
Jun-17-15Initiated Piper Jaffray Neutral
Apr-29-15Reiterated UBS Buy $64 → $68
Apr-29-15Reiterated Argus Buy $66 → $70
Apr-30-14Reiterated Argus Buy $62 → $66
Apr-11-14Reiterated MKM Partners Buy $64 → $70
Feb-05-14Reiterated Argus Buy $54 → $62
Jan-14-14Reiterated MKM Partners Buy $59 → $64
Jun-03-13Reiterated MKM Partners Buy $54 → $59
Apr-15-13Reiterated Barclays Overweight $45 → $60
Feb-04-13Reiterated MKM Partners Buy $51 → $52
Feb-04-13Reiterated Barclays Overweight $46 → $45
Nov-20-12Upgrade MKM Partners Neutral → Buy $47 → $51
Oct-17-12Reiterated MP Advisors Outperform $45 → $50
Jul-30-12Reiterated UBS Buy $45 → $50
Jul-13-12Upgrade MP Advisors Market Perform → Outperform $45
Apr-29-16 08:27PM  Gilead Judge Re-Opens Case Amid Claim Merck Scientist Lied at Bloomberg
04:01PM  The 4 Stocks That Weighed on the DJIA Friday at 24/7 Wall St.
02:02PM  Here's Why Merck Has More Downside Ahead at TheStreet
11:16AM  Gilead Sciences, Inc. Reports Disappointing Q1 Harvoni Sales at Motley Fool
Apr-28-16 11:28PM  Gilead Disappoints, Harvoni Sales Drop 16% Yahoo Finance Contributors
08:01PM  9 Figures That Sum Up Gilead Sciences' First Quarter at Motley Fool
04:37PM  [$$] Gilead reports drop in Hepatitis C Drug Revenue at The Wall Street Journal
03:49PM  Traders show caution on Merck earnings optionMONSTER
11:07AM  What Developments Did Merck & Co. See during 1Q16? Market Realist
09:04AM  3 Healthcare Stocks Billionaires Love Right Now at Motley Fool
09:00AM  Will Gileads Run Come to an End this Quarter? Yahoo Finance Contributors
08:00AM  Christina Applegate and Merck Urge Insomnia Sufferers to Learn "Why They're So Awake" PR Newswire
Apr-27-16 06:04PM  Merck sex discrimination case could be collective action -judge Reuters
09:15AM  Major Pharma Short Interest Remains Mixed, With 1 Massive Drop at 24/7 Wall St.
08:00AM  Merck, the American Diabetes Association and America's Diabetes Challenge Celebrity Voices Unite to Take on National Health Epidemic PR Newswire
Apr-26-16 03:28PM  Will Merck & Co.s Revenue Recover Growth in 1Q16? Market Realist
03:28PM  Merck & Co.s 1Q16 Estimates Show Revenue Growth Market Realist
11:39AM  Journal of the American Medical Association Publishes Phase III Data from Allergic Asthma Trial with ALK's House Dust Mite SLIT-tablet, ACARIZAX® PR Newswire
08:00AM  New ranking crowns JPMorgan the top US company for diversity and inclusion at CNBC
Apr-25-16 04:25PM  5 Stocks With Bigger Dividends Than Merck & Co. at Motley Fool
10:58AM  Healthcare Q1 Earnings Look Solid: ETFs to Benefit Zacks
05:15AM  Management and Strategies Count Most Yahoo Finance Contributors
Apr-23-16 03:53PM  Five Healthcare Stocks Added to HealthInvest Partners Portfolio in Q1 at Insider Monkey
03:16PM  3 Things to Watch in Gilead Sciences, Inc.'s First-Quarter Results at Motley Fool
Apr-21-16 03:59PM  Why Relypsa Spiked Today and a Letter to the CEO Yahoo Finance Contributors
Apr-20-16 07:47AM  One and Done...and More! Yahoo Finance Contributors
07:00AM  New Treatment Now Available for Canadians with Metastatic Non-Small Cell Lung Cancer CNW Group
Apr-19-16 05:00PM  Merck Animal Health to Acquire Worldwide Rights to Whisper® Veterinary Stethoscope System Business Wire
02:05PM  Merck Statement on Blueprint Project Findings Presented at the American Association for Cancer Research 2016 Annual Meeting Business Wire
01:22PM  [$$] Roche 'very optimistic' on prospects for new cancer drugs at Financial Times
12:25PM  16 Reasons to Buy Merck and Never Sell at Motley Fool
09:06AM  What Do Analysts Recommend for Medivation?
08:21AM  [$$] Supply Chain Analytics Company FusionOps Grabs $25M at The Wall Street Journal
Apr-18-16 05:18PM  The Two Mercks Are Locking Horns in a Naming Trademark Spat at Fortune
11:07AM  Could Xtandis Use for Breast Cancer Be a Valuation Driver?
09:02AM  [$$] Clinical Development News, April 11-15 at The Wall Street Journal
08:00AM  Merck Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for KEYTRUDA® (pembrolizumab) in Classical Hodgkin Lymphoma (cHL) Business Wire
05:15AM  Disappointed over G-20 and Doha Meetings
Apr-17-16 03:27PM  Relypsa's Wild Rumors and the Facts that Were Ignored
Apr-16-16 09:36AM  Valeant vs. Abbott Labs: Which Is Better for My Portfolio? (VRX, ABT) at Investopedia
01:00AM  Merck Announces Results From Phase 3 Studies of ZEPATIER (Elbasvir and Grazoprevir) in Chronic Hepatitis C Patient Populations at The International Liver Congress Business Wire
Apr-15-16 07:41PM  Merck CEO Kenneth Frazier Sells 131,040 Shares
11:22AM  [$$] Best Bets in Biopharma at Barrons.com
Apr-14-16 05:45PM  New tests for choosing right hep C drug could save money
04:30PM  Stand Up To Cancer launches new industry-supported research program at bizjournals.com
04:01PM  The 4 Stocks That Buoyed the DJIA on Thursday at 24/7 Wall St.
02:21PM  Stocks fight for gains after earnings disappoint, jobless claims drop at MarketWatch
12:20PM  Drug giant plots Peninsula expansion, 150 more jobs at bizjournals.com
11:20AM  Merck Offers Positive Data from Comparative Trial on Zepatier
01:00AM  Mercks ZEPATIER (Elbasvir and Grazoprevir) Showed Superiority on Efficacy and Safety Endpoints Compared to Sofosbuvir Plus Peginterferon and Ribavirin Treatment Regimen in Phase 3 Trial Business Wire
12:01AM  Double-Digit Growth In Drug Spending Slows As Insurers Fight Back at Forbes
Apr-13-16 08:09AM  [$$] FDA to Review Merck's Keytruda for Head and Neck Cancer at The Wall Street Journal
08:04AM  Merck Says FDA Accepts Its sBLA For Keytruda And Grants Priority Review
07:00AM  FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) in Recurrent or Metastatic Head and Neck Cancer, and Grants Priority Review Business Wire
01:15AM  License application for investigational house dust mite SLIT-tablet accepted for review by FDA GlobeNewswire
Apr-12-16 02:04PM  Gilead Sciences: Expect a Miss? at Barrons.com
09:50AM  Short Sellers Become More Selective in Major Pharma at 24/7 Wall St.
Apr-11-16 03:55PM  Genentech moves to drug-approval fast lane as immunotherapy speeds up at bizjournals.com
11:38AM  2 Big Pharma Stocks That Offer Market-Beating Growth Amid Turmoil at TheStreet
10:37AM  Stocks Up; Volume Mixed; Early Risers: Seagate, Yahoo, LGI Homes
09:47AM  Stocks Open With Decent Gains; Ore, Gold Miners Buzzing
06:57AM  How Best To Address The Increase In Liver Cancer Deaths at Forbes
05:14AM  Politicians Impede Prosperity
Apr-09-16 06:42AM  The Biggest Threat to Novavax Stock at Motley Fool
Apr-08-16 09:00PM  If Only Banks Were Utilities: Pharma's in the Doghouse: Jim Cramer's Best Blogs at TheStreet
09:00AM  Its True. Quality Leads Market Returns in Narrow Breadth Markets.
09:00AM  Taking the Pulse of These Healthcare Giants - PFE, MRK, JNJ, and ABBV Accesswire
08:00AM  Merck to Hold First-Quarter 2016 Sales and Earnings Conference Call on May 5 Business Wire
Apr-07-16 03:42PM  Relypsas Bullish Thesis Goes Further than Takeover Rumors
09:01AM  Merck (MRK) Stock Gets 'Buy' Rating at Societe Generale at TheStreet
08:00AM  Merck Highlights Ongoing Commitment to Fighting Infectious Diseases with More Than 30 Data Presentations at ECCMID 2016 Business Wire
Apr-06-16 06:08PM  Merck CEO: Here's the real issue with business tax at CNBC
04:40PM  Merck CEO: Current tax system makes US companies uncompet...
04:18PM  XLV Large Caps: Pfizer Moves Up on Inflectra Approval from FDA
04:01PM  The 4 Stocks That Dominated the Dow on Wednesday at 24/7 Wall St.
02:26PM  PPH May Be Home To Hedge Fund Hotels, But This ETF Can Endure
11:47AM  Coverage initiated on Merck by Societe Generale
08:00AM  Merck to Present New Data for KEYTRUDA® (pembrolizumab) at the American Association for Cancer Research 2016 Annual Meeting Business Wire
07:30AM  Merck CEO Ken Frazier Is Looking Smart For Avoiding A Tax Inversion at Forbes
Apr-05-16 07:02PM  Cramer: Allergan Shows Pharma Is Back in the Political Doghouse
06:12PM  [$$] FDA Approves Rheumatoid Arthritis Knockoff at The Wall Street Journal
04:40PM  Wall Street closes lower for 2nd day as earnings, overseas worries weigh at MarketWatch
11:13AM  [$$] Lilly Cholesterol Data Impacts Merck, Esperion at Barrons.com
09:43AM  Bears Drive Early Stock Action; Rule Change Trips Allergan
08:00AM  Advaxis Combination Trial with Merck Completes First Two Dose-Escalation Cohorts GlobeNewswire
06:36AM  Feds Rosengren Has It Wrong!
Apr-04-16 04:14PM  Fed Worries, Crude Oil Team Up to Beat Down Wall Street at TheStreet
01:23PM  Stocks Show Tiny Losses; Michael Kors Outperforms
12:22PM  Biotech: Time to Buy? at Barrons.com
10:58AM  Gilead Sciences Rise on Hepatitis C Strength (GILD, MRK) at Investopedia
08:44AM  Better Buy: Gilead Sciences Inc. vs. Biogen Inc. at Motley Fool
Apr-03-16 11:24PM  VWELX: Vanguard Wellington Fund Top 5 Holdings Analysis at Investopedia
03:02PM  Patent Palooza: One Patent Battle in Hep C, And Another Patent Brawl Brewing On Capitol Hill at Motley Fool
11:05AM  Some People Really Can't Take Statins For High Cholesterol, Scientists Prove at Forbes
09:00AM  New cholesterol methods needed in wake of failed drugs, heart researchers say
Apr-02-16 07:12PM  3 Best Dividend-Paying U.S. Health Care Mutual Funds (VGHCX, BMY) at Investopedia
02:18PM  Ebola Can Teach Investors an Important Lesson About Economic Viability at Motley Fool
Apr-01-16 04:08PM  Market Response to EMA Validation of Opdivo Application
04:08PM  Checkmate-205: Studies Supporting Opdivos Application
03:03PM  How Big of a Deal Are Gilead Sciences Patent Woes? at Motley Fool
Merck & Co., Inc. provides health care solutions worldwide. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. It also provides neuromuscular blocking agents for use in surgery; anti-bacterial products for skin and skin structure infections; cholesterol modifying medicines; non-sedating antihistamine; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors; treat melanoma and metastatic non-small-cell lung cancer; and prevent diseases caused by human papillomavirus, as well as vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it provides antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics for the treatment of C. difficile, and vaccines against bacterial and viral disease in fish. Additionally, the company offers companion animal products, such as ointments for acute and chronic otitis; diabetes mellitus treatment for dogs and cats; anthelmintic products; chewable tablets to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HARRISON WILLIAM B JRDirectorApr 13Option Exercise34.445,000172,20016,400Apr 13 03:03 PM
WEEKS WENDELL PDirectorNov 04Option Exercise34.445,000172,2005,100Nov 04 04:37 PM
WEEKS WENDELL PDirectorNov 04Sale55.535,000277,669100Nov 04 04:37 PM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerOct 29Option Exercise36.5637,3131,364,16357,008Oct 29 04:23 PM
FRAZIER KENNETH CChairman, President & CEOOct 29Option Exercise35.0918,666654,990456,902Oct 30 04:58 PM
FRAZIER KENNETH CChairman, President & CEOOct 29Sale54.6918,6661,020,758438,236Oct 30 04:58 PM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerOct 29Sale55.0837,3132,055,33419,695Oct 29 04:23 PM
WENDELL PETER CDirectorOct 28Option Exercise34.445,000172,2006,000Oct 28 02:44 PM
WENDELL PETER CDirectorOct 28Sale54.855,000274,2371,000Oct 28 02:44 PM
Holston Michael JEVP, General CounselAug 01Option Exercise0.0022,584062,584Aug 04 02:41 PM
Golestani ClarkEVP & Chief Info OfficerJul 31Option Exercise39.8335,5421,415,54643,994Aug 04 02:41 PM
Golestani ClarkEVP & Chief Info OfficerJul 31Sale59.0931,8311,880,80512,163Aug 04 02:41 PM
Schechter Adam HEVP & Pres-Global Human HealthMay 11Sale60.4410,634642,7680May 11 05:48 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyMay 08Option Exercise35.2846,2081,630,39670,353May 11 01:33 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyMay 08Sale60.9938,3682,339,94931,985May 11 01:33 PM
Kuhlik Bruce NExe V-P & Gen CounselMay 04Option Exercise39.2956,0642,202,755206,496May 05 04:46 PM
Kuhlik Bruce NExe V-P & Gen CounselMay 04Sale60.2056,0643,374,795150,432May 05 04:46 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyMay 02Option Exercise0.003,818025,359May 05 04:46 PM
Golestani ClarkEVP & Chief Info OfficerMay 02Option Exercise0.002,291010,259May 05 04:46 PM
GRADDICK WEIR MIRIAN MExe V-P, HRMay 02Option Exercise0.008,6540116,334May 05 04:46 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 02Option Exercise0.004,709015,129May 05 04:46 PM
Rosenblatt MichaelExec V-P & Chief Med OfficerMay 02Option Exercise0.003,818034,534May 05 04:46 PM
Schechter Adam HEVP & Pres-Global Human HealthMay 02Option Exercise0.0019,343019,343May 05 04:46 PM
Kuhlik Bruce NExe V-P & Gen CounselMay 02Option Exercise0.0011,7080156,503May 05 04:46 PM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerMay 02Option Exercise0.003,818020,794May 05 04:46 PM
Deese Willie AExe V-P & Pres. MMDMay 02Option Exercise0.007,6360122,631May 05 04:46 PM
DeLuca Richard R.EVP&Pres, Merck Animal HealthMay 02Option Exercise0.005,090014,564May 05 04:46 PM